ORIENT PHARMA's Listing on the Emerging Stock Market Approved, Poised for Q3 Debut

On the 9th, the Taipei Exchange reviewed and approved ORIENT PHARMA’s application to be listed on the emerging stock market. If all proceeds smoothly, the company is expected to go public in the third quarter.

ORIENT PHARMA is applying for listing under the technology sector. The company focuses on the development, manufacturing, and commercialization of 505(b)(2) new drugs and high-barrier niche generics, including Paragraph IV filings. The company is chaired by Tsai, Cheng-Hung. The sponsoring securities firms are MasterLink Securities, First Securities, and Taishin Securities. At the time of application, the company had a capital of NT$2.23035 billion.

For the fiscal year 2024, ORIENT PHARMA reported consolidated revenue of NT$1.222 billion, with a net profit after tax of NT$107 million and earnings per share (EPS) of NT$0.48. In the first quarter of 2025, the company recorded consolidated revenue of NT$316 million, with a net profit after tax of NT$50.57 million and an EPS of NT$0.23.

Resource: 友霖上櫃案通過審議，有望於Q3掛牌